Patent Protects DNA Display Technology

(Aberdeen, UK) for its DBDxT display technology. The patent protects the usage of this technology for display of proteins including antibody binding sites, the maintenance of large repertoires of different proteins, and the selection from these repertoires of specific therapeutic drug leads.

DBDxT has already been used in conjunction with Haptogen's Haptomics protocol to develop antibodies against specific signaling molecules produced by both Gram-positive and Gram-negative bacteria. Since these antibodies are not directed against the bacteria, it is felt that they will not drive the bacteria into developing resistance against them.

Dr. Jim Reid, CEO of Haptogen, said, "Using DBDx technology in combination with our unique HaptomicsT protocols and antibody libraries, we have developed a bio-selection process that we term FEST or Forced Epitope Selection. This facilitates the isolation of highly specific antibodies to targets usually considered beyond the scope of current immuno-technologies.”




Related Links:
Haptogen Ltd.